BioTuesdays

Tag - CRVS

Corvus Pharmaceuticals

Cantor starts Corvus Pharma at OW; PT $10

Cantor Fitzgerald launched coverage of Corvus Pharmaceuticals (NASDAQ:CRVS) with an “overweight” rating and 12-month price target of $10. The stock closed at $2.66 on May 26. “We believe that the risk/reward profile is...

Corvus Pharmaceuticals

HCW starts Corvus Pharma at buy; PT $10

H.C. Wainwright launched coverage of Corvus Pharmaceuticals (NASDAQ:CRVS) with a “buy” rating and $10 price target. The stock closed at $2.72 on March 9. Corvus is focused on developing precision medicines to treat...